PHIO PHARMACEUTICALS CORP. Form DEF 14A: Definitive proxy statement
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2026-08-14: Form DEF 14A; Period of report 2026-09-28; Description FORM DEF 14A; Document phio20251226_def14a.htm.
- 2025-07-30: Form DEF 14A; Period of report 2025-09-11; Description DEFINITIVE PROXY; Document phio_idef14a.htm.
- 2024-05-08: Form DEF 14A; Period of report 2024-06-17; Description DEFINITIVE PROXY STATEMENT; Document phio_def14a.htm.
- 2023-06-09: Form DEF 14A; Period of report 2023-07-20; Description DEFINITIVE PROXY STATEMENT; Document phio_def14a.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2026-08-14 | DEF 14A | 2026-09-28 | FORM DEF 14A | phio20251226_def14a.htm |
| 2025-07-30 | DEF 14A | 2025-09-11 | DEFINITIVE PROXY | phio_idef14a.htm |
| 2024-05-08 | DEF 14A | 2024-06-17 | DEFINITIVE PROXY STATEMENT | phio_def14a.htm |
| 2023-06-09 | DEF 14A | 2023-07-20 | DEFINITIVE PROXY STATEMENT | phio_def14a.htm |
| 2022-11-30 | DEF 14A | 2023-01-04 | DEFINITIVE PROXY | phio_def14a.htm |
| 2022-06-30 | DEF 14A | 2022-08-09 | DEFINITIVE PROXY | phio_def14a-080922.htm |
| 2021-04-30 | DEF 14A | 2021-06-15 | DEF 14A | phio_def14a.htm |
| 2020-08-28 | DEF 14A | 2020-10-08 | DEFINITIVE PROXY STATEMENT | phio_def14a.htm |
| 2019-11-22 | DEF 14A | 2019-12-12 | DEFINITIVE PROXY | phio_def14a.htm |
| 2019-08-30 | DEF 14A | 2019-08-22 | DEFINITIVE PROXY STATEMENT | phio_def14a.htm |
| 2018-04-26 | DEF 14A | 2018-06-05 | DEF 14A | d563605ddef14a.htm |
| 2017-04-27 | DEF 14A | 2017-06-06 | DEF 14A | d366780ddef14a.htm |
| 2016-11-04 | DEF 14A | 2016-12-15 | DEF 14A | d268475ddef14a.htm |
| 2016-03-07 | DEF 14A | 2016-04-14 | DEF 14A | d291334ddef14a.htm |
| 2015-04-16 | DEF 14A | 2015-06-01 | DEF 14A | d902092ddef14a.htm |
| 2014-04-15 | DEF 14A | 2014-06-02 | DEF 14A | d703460ddef14a.htm |
| 2013-04-26 | DEF 14A | 2013-06-07 | DEF 14A | d524399ddef14a.htm |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |